Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 1 (1)

Trial Status

Enrolling By Invitation3
Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT04049084Enrolling By Invitation

An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID

NCT01852370Phase 1Enrolling By InvitationPrimary

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

NCT06659588Recruiting

Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency

NCT01186913Enrolling By InvitationPrimary

Natural History Study of SCID Disorders

Showing all 4 trials

Research Network

Activity Timeline